DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Firmagon (Degarelix Acetate) - Summary

 
 



FIRMAGON SUMMARY

FIRMAGON is a sterile lyophilized powder for injection containing degarelix (as the acetate) and mannitol. Degarelix is a synthetic linear decapeptide amide containing seven unnatural amino acids, five of which are D-amino acids.

FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.


See all Firmagon indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Firmagon (Degarelix)

Cost-effectiveness analysis comparing degarelix with leuprolide in hormonal therapy for patients with locally advanced prostate cancer. [2013]
Degarelix, approved in the USA in 2008, is a gonadotropin-releasing hormone antagonist, representing one of the latest additions to androgen deprivation therapy (ADT). ADT is used as first-line therapy for locally advanced or metastatic prostate cancer with the aim to reduce testosterone to castrate levels...

Degarelix versus goserelin (+ antiandrogen flare protection) in the relief of lower urinary tract symptoms secondary to prostate cancer: results from a phase IIIb study (NCT00831233). [2013]
prostate cancer (PrCa)... CONCLUSION: In 40 men with predominantly locally advanced PrCa and highly

Efficacy and safety of androgen deprivation therapy after switching from monthly leuprolide to monthly degarelix in patients with prostate cancer. [2011]
testosterone suppression or safety profile during the first 3 months... CONCLUSIONS: This 3-month analysis indicates that patients with prostate cancer

Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. [2010]
gonadotropin-releasing hormone antagonist... CONCLUSIONS: In men with prostate cancer degarelix and leuprolide have similar

Degarelix. [2009]
Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that, in common with GnRH receptor agonists (e.g. leuprolide, goserelin and triptorelin), is indicated for use as an androgen-deprivation therapy in patients with advanced prostate cancer...

more studies >>

Clinical Trials Related to Firmagon (Degarelix)

A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy [Completed]
Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5 years.

Investigation of a New Trial Drug (FE200486) in Prostate Cancer Patients [Completed]

The purpose of this trial was to find an optimal dose for a new trial drug - degarelix

(FE200486) - in the treatment of prostate cancer. Furthermore the safety of the drug was

studied. Patients participating were treated with FE200486 on one occasion. Thereafter they came in for visits following a specific schedule until blood samples showed that there was no further effect.

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients [Terminated]

Extension Study Investigating the Long-Term Safety and Tolerability of Repeat Doses of FE200486 in Prostate Cancer Patients [Terminated]
Participants responding well in Study FE200486 CS06 (NCT00117949) were given the opportunity to continue treatment with degarelix under a clinical study until FE200486 was available on the market or until the study was discontinued. Study FE200486 CS06A was to provide knowledge of the long-term safety and tolerability of FE200486.

A Degarelix Trial in Patients With Prostate Cancer [Terminated]
A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot with the established therapy Zoladex 3 month implant in patients with prostate cancer.

more trials >>

Reports of Suspected Firmagon (Degarelix) Side Effects

Injection Site Pain (14)Fatigue (13)Asthenia (12)Injection Site Erythema (11)Pyrexia (10)Abdominal Pain (8)Headache (8)Dyspnoea (7)Malaise (6)Palpitations (6)more >>


Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015